DR. JOHN DORRANCE MINNA, MD
Osteopathic Medicine at Harry Hines Blvd, Dallas, TX
License number
Texas J2859
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
5323 Harry Hines Blvd, Dallas, TX 75390
Phone
(214) 645-8600
Personal information
See more information about JOHN DORRANCE MINNA at radaris.comName
Address
Phone
2622 Thomas Ave, Dallas, TX 75204
5323 Harry Hines Blvd, Dallas, TX 75235
3131 Maple Ave #11G, Dallas, TX 75201
4007 Stonebridge Dr, Dallas, TX 75204
2618 Thomas Ave, Dallas, TX 75204
Professional information
Dr. John D Minna, Dallas TX - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
UT Southwest Medical Center
5323 Harry Hines Blvd SUITE NB8206, Dallas 75390
(214) 648-4900 (Phone)
5323 Harry Hines Blvd SUITE NB8206, Dallas 75390
(214) 648-4900 (Phone)
Certifications:
Internal Medicine, 1973, Medical Oncology, 1977
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Education:
Medical School
Stanford University School Of Medicine
Graduated: 1967
Massachusetts General Hospital
Graduated: 1968
Graduated: 1969
Stanford University School Of Medicine
Graduated: 1967
Massachusetts General Hospital
Graduated: 1968
Graduated: 1969
John Dorrance Minna, Dallas TX
Specialties:
Oncologist
Address:
5323 Harry Hines Blvd, Dallas, TX 75390
Utah Southwestern Medical Ctr, Dallas, TX 75390
Utah Southwestern Medical Ctr, Dallas, TX 75390
Education:
Stanford University, School of Medicine - Doctor of Medicine
Massachusetts General Hospital - Residency - Internal Medicine
Massachusetts General Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Polymorphic Repeats In Human Genes
US Patent:
6472154, Oct 29, 2002
Filed:
Dec 31, 1999
Appl. No.:
09/475947
Inventors:
Harold R. Garner - Flower Mound TX
Jonathan D. Wren - Irving TX
John D. Minna - Dallas TX
Jonathan D. Wren - Irving TX
John D. Minna - Dallas TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C12Q 168
US Classification:
435 6, 536 231
Abstract:
The invention provides computational methods and compositions for identifying polymorphic repeats in genes. Candidate polymorphic repeats are identified by detecting tandem repeats in a target coding sequence, scoring the repeats for polymorphic probability, and generating a dataset correlating the repeats with polymorphic probability. Actual polymorphic repeat are identified by further detecting the candidate polymorphic repeat in each of a population of different coding sequences, and determining whether the candidate polymorphic repeat is polymorphic in the population. Computationally derived polymorphic repeats are validated with phenotypic variations and these correlates are used to detect the presence or absence of such phenotypic variation in test genes. Variances at polymorphic repeats are identified by detecting in a test gene or coding region the presence or absence of variance at a disclosed unconventional polymorphic repeat.
Methods And Compositions For The Stimulation Of Human Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes Employing Autologous Antigen-Peripheral Blood Mononuclear Cells
US Patent:
2003008, May 8, 2003
Filed:
Sep 19, 2002
Appl. No.:
10/251125
Inventors:
Jay Berzofsky - Bethesda MD, US
Michael Yanuck - Bethesda MD, US
David Carbone - Dallas TX, US
John Minna - Dallas TX, US
Hidemi Takahashi - Tokyo, JP
Michael Yanuck - Bethesda MD, US
David Carbone - Dallas TX, US
John Minna - Dallas TX, US
Hidemi Takahashi - Tokyo, JP
Assignee:
Department of Health and Human Services - Rockville MD
International Classification:
A61K045/00, C12N005/08, C12Q001/68, A01N063/00, A01N065/00
US Classification:
424/093700, 435/372000, 435/006000
Abstract:
A novel method of immunization, which can be used either prophylactically or therapeutically, is described. The method comprises coating of antigen presenting cells with a peptide and administering the peptide-coated cells to a mammalian subject to provoke an immune response. Useful peptides include peptides derived from viral or bacterial antigens or mutant oncogene or tumor suppressor gene products. Immunogens, constituted by the peptide-coated cells, are also described.
Methods And Compositions Using Peptide-Pulsed Dendritic Cells For Stimulating Cytotoxic T Lymphocytes Specific For Tumor Cells Or Virus-Infected Cells
US Patent:
2003003, Feb 13, 2003
Filed:
Sep 19, 2002
Appl. No.:
10/251172
Inventors:
Jay Berzofsky - Bethesda MD, US
Michael Yanuck - Bethesda MD, US
David Carbone - Dallas TX, US
John Minna - Dallas TX, US
Hidemi Takahashi - Tokyo, JP
Michael Yanuck - Bethesda MD, US
David Carbone - Dallas TX, US
John Minna - Dallas TX, US
Hidemi Takahashi - Tokyo, JP
Assignee:
The Govt. of the U.S.A., as represented by the Secretary of the Department of H & H Services - Rockville MD
International Classification:
A61K039/21, A61K039/00, C12N005/08, C12Q001/68, A61K039/38, C12N005/00, C12N005/02
US Classification:
435/006000, 435/325000, 424/188100, 424/184100
Abstract:
A novel method of immunization, which can be used either prophylactically or therapeutically, is described. The method comprises coating of antigen presenting cells with a peptide and administering the peptide-coated cells to a mammalian subject to provoke an immune response. Useful peptides include peptides derived from viral or bacterial antigens or mutant oncogene or tumor suppressor gene products. Immunogens, constituted by the peptide-coated cells, are also described.
Identification Of Chemically Modified Polymers
US Patent:
2003015, Aug 14, 2003
Filed:
Jun 27, 2002
Appl. No.:
10/184085
Inventors:
Harold Garner - Coppell TX, US
John Minna - Dallas TX, US
Kevin Luebke - Dallas TX, US
Robert Balog - Dallas TX, US
John Minna - Dallas TX, US
Kevin Luebke - Dallas TX, US
Robert Balog - Dallas TX, US
International Classification:
C12Q001/68
US Classification:
435/006000
Abstract:
The present invention provides a high-throughput method for the parallel analysis of many potential sites of chemical modification (e.g., methylation) in DNA. It makes use of chemical treatment of the DNA to alter its sequence in a way that depends upon the modification of interest and subsequent analysis of the resulting sequence by hybridization to an array of probes. A device, comprising the array of probes, is provided by the invention, and principles and methods for its design and fabrication are also provided.
Modulation Of Gene Expression By Oligomers Targeted To Chromosomal Dna
US Patent:
8324181, Dec 4, 2012
Filed:
Mar 30, 2010
Appl. No.:
12/750201
Inventors:
David R. Corey - Dallas TX, US
David S. Shames - Dallas TX, US
Bethany A. Janowski - Dallas TX, US
John D. Minna - Dallas TX, US
David S. Shames - Dallas TX, US
Bethany A. Janowski - Dallas TX, US
John D. Minna - Dallas TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 31/70, C07H 21/04
US Classification:
514 44, 536 245
Abstract:
Synthesis of a target transcript of a gene is selectively increased in a mammalian cell by contacting the cell with a polynucleotide oligomer of 12-28 bases complementary to a region within a target promoter of the gene under conditions whereby the oligomer selectively increases synthesis of the target transcript.
Chromosome 3P21.3 Genes Are Tumor Suppressors
US Patent:
2012007, Mar 29, 2012
Filed:
May 24, 2011
Appl. No.:
13/114921
Inventors:
Lin Ji - Sugar Land TX, US
John Dorrance Minna - Dallas TX, US
Jack Roth - Houston TX, US
Michael Lerman - Rockville MD, US
John Dorrance Minna - Dallas TX, US
Jack Roth - Houston TX, US
Michael Lerman - Rockville MD, US
International Classification:
A61K 31/711, A61K 9/127, A61P 35/00, A61K 31/7048, A61K 31/713, C12N 5/09, A61K 33/24
US Classification:
424450, 435325, 514 44 R, 424649, 514 34, 514 32, 514 27, 514 44 A
Abstract:
Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.
Sema3B Inhibits Tumor Growth And Induces Apoptosis In Cancer Cells
US Patent:
7781413, Aug 24, 2010
Filed:
Oct 31, 2002
Appl. No.:
10/285351
Inventors:
John Minna - Dallas TX, US
Yoshio Tomizawa - Takasaki, JP
Yoshitaka Sekido - Nagoya, JP
Michael Lerman - Rockville MD, US
Yoshio Tomizawa - Takasaki, JP
Yoshitaka Sekido - Nagoya, JP
Michael Lerman - Rockville MD, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 31/713
US Classification:
514 44R, 536 235, 530350, 514 2, 4353201, 435375
Abstract:
The present invention identifies the semaphorin polypeptide SEMA3B as a tumor suppressor. This molecule can inhibit tumor growth and induce apoptosis of tumor cells when produced internally in a cancer cell via gene transfer, or when applied extracellularly. These observations permit new methods for treatment and diagnosis of cancer.
Chromosome 3P21.3 Genes Are Tumor Suppressors
US Patent:
2012010, May 3, 2012
Filed:
Jan 9, 2012
Appl. No.:
13/346528
Inventors:
Lin Ji - Sugar Land TX, US
John Minna - Dallas TX, US
Jack Roth - Houston TX, US
Michael Lerman - Rockville MD, US
John Minna - Dallas TX, US
Jack Roth - Houston TX, US
Michael Lerman - Rockville MD, US
International Classification:
A61M 37/00, A61P 35/00, A61K 9/127, C12N 5/09, A61K 38/12, A61K 31/7048, A61K 38/14, A61K 31/7088, A61K 33/24
US Classification:
600 1, 514 44 R, 424450, 424649, 514 199, 514 34, 514 44 A, 435325, 604 20
Abstract:
Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.